25I-NBMD

25I-NBMD is a psychedelic and hallucinogenic drug that is part of the 2C family. It was first synthesized and documented in 2011 by Thomas McLean and David E. Nichols at Purdue University. They described it as a potent partial agonist for the 5-HT2A receptor.

History

The first synthesis of 25I-NBMD was reported in 2011 by Thomas McLean and David E. Nichols at Purdue University. They were working on a project to develop serotonin 5-HT2A receptor partial agonists as potential therapeutic agents. The compound was later found to have psychedelic properties.

Pharmacology

25I-NBMD acts as a potent partial agonist for the 5-HT2A receptor. The exact nature of the drug's effects and its full range of potential uses are not well understood, as it has not been extensively studied in humans.

Effects

The effects of 25I-NBMD are similar to those of other hallucinogenic drugs. Users report intense visual hallucinations, altered thinking processes, and a sense of euphoria. However, the drug can also cause negative effects such as anxiety, paranoia, and potentially dangerous changes in heart rate and blood pressure.

Legal Status

The legal status of 25I-NBMD varies by country. In the United States, it is classified as a Schedule I drug under the Controlled Substances Act. In the United Kingdom, it is a Class A drug under the Misuse of Drugs Act 1971.

See Also

• 25I-NBOMe
• 25C-NBOMe
• 25B-NBOMe
• Psychedelic drug
• Hallucinogen

References

25I-NBMD Resources
Latest articles Most recent articles Ongoing trials	Wikipedia